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Editor’s note: The previous issue of the SAJHIV (December 2011) 
carried an Opinion piece by Innes, Cotton and Venter regarding 
the potential value of low-dose of stavudine (20 mg twice a day). 
They suggested that reduced dosing of stavudine may lead to 
levels of viral suppression comparable with those achieved with 
stavudine 30 mg bd but with a lower risk of toxicity and side-
effects, and at a fraction of the cost of tenofovir. The Opinion 
was related to a larger proposal, led by Venter, to conduct a 
head-to-head trial comparing low-dose stavudine with tenofovir 
(both in a regimen including lamivudine and efavirenz) on viral 
suppression and other  treatment outcomes over 24 months. 
There has been considerable debate regarding the  advantages 
and disadvantages of low-dose stavudine, and in turn the value 
of any such trial. Here the debate continues with a commentary 
by Isabelle Andrieux-Meyer et al. and a rebuttal by Venter and 
colleagues.
We read with interest an opinion piece by Innes et al.1 in the previous 
issue of the journal, regarding the potential value of low-dose 
stavudine (20 mg twice daily). The article focused on stavudine 
use in paediatrics (where there are fewer approved antiretrovirals 
compared with adults, although there will be greater choice in 
the near future, as the US Food and Drug Administration (FDA) 
has recently approved tenofovir for 2 - 12-year-olds, and other 
regulatory agencies are expected to follow suit). In the article, the 
authors used the situation with children to argue for a proposal, 
led by Venter, to conduct a head-to-head non-inferiority study 
in adults comparing low-dose stavudine with tenofovir (both in 
a regimen including lamivudine and efavirenz) with a 48-week 
virological endpoint and other treatment outcomes over 96 
weeks.* We have serious concerns about this proposed trial, for the 
following reasons:
1. Stavudine is more toxic than tenofovir, and for this 
reason it is an inferior treatment option. The proposed trial 
aims to establish virological non-inferiority, which is a moot 
point, given the severe adverse events associated with stavudine.   
Considerable evidence supports the use of tenofovir over stavudine; 
regulatory bodies and the World Health Organization (WHO) have 
turned away from the drug. In 2004, stavudine was removed from 
the list of preferred first-line antiretroviral drugs recommended 
by the US Department of Health and Human Services (DHHS).2 
Starting in 2006, the WHO recommended that countries start 
moving away from stavudine, and in 2009 recommended that 
the drug be phased out in first-line antiretroviral therapy (ART) 
programmes.3 Earlier this year, the European Medicines Agency 
(EMA) revised the indication for stavudine, noting that ‘… the 
use of the medicine should be severely restricted in both adults 
and children ... Prescribers are reminded of the severe side effects 
seen with Zerit [stavudine] and should only use the medicine when 
other appropriate treatments are not available. Patients being 
treated with Zerit should be assessed frequently and switched to 
appropriate alternatives as soon as possible.’4
Médecins Sans Frontières (MSF)/Doctors Without Borders have 
provided further compelling evidence of stavudine’s toxicity in 
an operational setting. In a Lesotho cohort, the authors found 
that ‘… for patients on stavudine, the risk of a toxicity-driven 
regimen switch was almost six times higher than tenofovir’.5 The 
high incidence of adverse events among patients on stavudine-
containing first-line regimens has also been documented in a 
larger prospective study in South Africa.6 In that study 30% of 
patients had to switch from stavudine-based to non-stavudine-
based regimens within 3 years.
For good reasons, tenofovir has become the gold standard 
for today’s first-line antiretroviral therapy. Its introduction in 
developing countries is an important step towards bringing 
treatment in poor countries in line with rich ones. As the WHO 
and all countries are phasing out stavudine, this study will send 
a confusing message, and it may slow down this transition while 
countries wait for the results.
*A randomised, double-blind study to demonstrate non-inferiority of stavudine 
(20 mg BID) compared with tenofovir (300 mg QD) co-administered with lamivudine 
and efavirenz in antiretroviral-naive patients over 96 weeks. If funded and approved, 
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There is no prospect that stavudine 20 mg is a better option than 
tenofovir. The stavudine parallel track programme, in which over 
10 000 patients were randomised to receive 40 (30) mg or 20 (15) 
mg between October 1992 and February 1994, showed a higher 
incidence of neuropathy in the high-dose arm (21%). Nonetheless, 
the incidence of neuropathy observed in the lower-dose arm was 
also unacceptably high (15%).7
Of particular importance in low- to middle-income countries – 
where tuberculosis (TB) is prevalent among HIV-positive people, 
who are also receiving stavudine-containing regimens – a South 
African study looked at the risk of stavudine substitution for 
toxicities in 7 066 patients receiving ongoing TB treatment at 
ART initiation; concurrent initiation of TB treatment and ART and 
incident TB treatment after ART initiation. The study found people 
receiving ongoing and concurrent TB treatment to be at increased 
risk of toxicity leading to stavudine substitution, irrespective 
of stavudine dose (30 and 40 mg). For ongoing TB treatment, 
adjusted hazard ratio (aHR) was 3.18 (95% confidence interval 
(CI) 1.82 - 5.56) in the first 2 months of ART; for concurrent TB 
treatment, aHR was 6.60 (95% CI 3.03 - 14.37) in the first 2 months 
of ART.
The stavudine 20 mg study is not being proposed in any developed 
country. Instead it is planned to include only middle- and lower-
income developing countries. Patients enrolling in this trial risk 
being randomised to receive treatment that may be less effective 
and is more toxic than the current standard of care. There is 
therefore no good reason why a properly informed patient should 
want to enrol in this study.
2. The poor tolerability of stavudine limits therapeutic 
durability. A person has the best chance of successful treatment 
with their first-line regimen, making it critical that the medicines 
are as tolerable as possible. A tolerable first-line regimen enhances 
therapeutic durability by helping people adhere to treatment, and 
delays their need to switch to more costly second-line regimens, 
which are complicated for patients, for health workers and from an 
operational standpoint.
3. Stavudine’s side-effects cut into stavudine’s savings on 
cost. A study published by MSF shows that inpatient care and 
essential drug costs were higher for people on stavudine than 
for those on tenofovir in a cohort in rural Lesotho. According to 
MSF’s cost-effectiveness study of switching from stavudine or 
zidovudine- to tenofovir-based first-line regimens in Lesotho, 
the tenofovir-containing regimen generated higher life years and 
quality-adjusted life years than zidovudine or stavudine-based 
treatment.8 As the costs of tenofovir and especially efavirenz drop, 
the cost benefit to patients and to health systems will become 
clearer. Since the study was completed, the global best price of 
efavirenz – which partly drives tenofovir costs – has almost halved 
(US$97 per patient year in 2009 to $52 today).
4. Stavudine can compromise second-line options. When 
someone does fail their first-line regimen, the longer they remain 
on stavudine – which is likely in a context with limited access 
to viral load monitoring – the more their second-line options 
are compromised. Unlike stavudine, tenofovir does not confer 
thymidine analogue mutations (TAMs); people taking tenofovir 
can stay on a failing regimen much longer without compromising 
efficacy of zidovudine and therefore second-line therapy.
5. Stavudine’s long-term toxicity question will not be 
answered by this trial. The proposed 20 mg stavudine dose might 
be acceptable in a short-term 48- or even 96-week virological 
endpoint study (although Bristol-Myers Squibb studied and 
rejected 20 mg bd). But, because mitrochondrial toxicity is both 
dose and time dependent, many of stavudine’s most serious side-
effects (such as peripheral neuropathy and lipoatrophy) would 
not necessarily emerge until after such a study was completed. 
This study does not include monitoring of surrogate markers for 
mitochondrial toxicity, so it cannot shed light on the incidence of 
this serious adverse event. 
Recently published longer-term Cambodian data on rates of 
severe stavudine-associated toxicity show 7% of people to have 
neuropathy within the first year; by year 3 the cumulative incidence 
was 16.6%, and it rose to 19.0% at year 6. The cumulative incidence 
of lipoatrophy was 56% by year 3 and 72% by year 6. Stavudine use 
significantly increased the risk for lactic acidosis among people on 
concurrent TB treatment; the aHR was 8.6 (95% CI 2.7 - 27.5).10 
The investigators have agreed that this important question about 
longer-term toxicity will not be answered in the trial, raising the 
serious issue that the trial will not be able to answer the primary 
policy question which drives it – whether long-term 20 mg 
stavudine twice daily is as good as once-daily tenofovir in first-line 
ART regimens for use in public health programmes in resource-
limited settings. 
6. Stavudine must be taken twice a day, compared with 
tenofovir’s once-daily dosing. A twice-daily dosing regimen 
(as with stavudine 20 mg) does not have the simplicity of a once-
daily fixed-dose combination (as with tenofovir). People are more 
likely to adhere to simpler regimens and therefore are more likely 
to have better treatment outcomes, as well as stave off resistance 
that requires more complex and expensive second-line regimens.
7. A tenofovir-based regimen is recommended for HIV/
hepatitis B (HBV) coinfection, because stavudine has 
no activity against HBV and resistance to lamivudine is 
inevitable. While HIV/HBV co-infection is an exclusion criterion 
for this trial, it may encourage persistent use of a suboptimal 
regimen for HIV/HBV co-infected people. Screening for HBV 
is not routinely performed before initiation of ART in most 
resource-limited settings, yet HBV is endemic. For example, in 
South Africa an estimated 5% of HIV-positive people are HBV co-
infected (Dr Mark Sonderup, personal communication). Giving 
a stavudine/lamivudine-based regimen to HIV/HBV co-infected 
people will create lamivudine-resistant HBV in this population 
(90% at 4 years).9 Continuing lamivudine in the context of HBV 
drug resistance may lead to hepatitis flares; these flares can 
cause serious liver damage, and are potentially life-threatening. 
Researchers are also concerned about the transmission of drug-
resistant HBV that may not be preventable by currently available 
HBV vaccines, a potential public health catastrophe. 
8. Stavudine-related cost savings may become irrelevant by 
the trial’s end. The rationale for this trial is to lower treatment 
costs, as stavudine is currently cheaper than its alternatives. 
However, the price of alternatives, notably tenofovir, has come 
down dramatically in the last several years, and is expected to 
decrease further as demand increases. According to MSF’s annual 
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the price of single-drug tenofovir having decreased by 52% from 
2008 to 2011, and the price of the triple fixed-dose combination 
of tenofovir, lamivudine and efavirenz having decreased by 53% to 
US$173 per person per year over that same time period.10 The price 
of the double FDC TDF/3TC co-packed with EFV is $143 per person 
per year. Furthermore, the Clinton Health Access Initiative (CHAI) 
is currently working on the in the reformulation of tenofovir, with 
the goal of increasing bioavailability, hence reducing the required 
active pharmaceutical ingredient and in turn the cost.
Because the stavudine 20 mg 96-week efficacy trial is expected to 
be completed at the earliest by 2014 - 2015, and would need to be 
followed by a larger, longer (perhaps 5-year) field effectiveness 
trial to determine longer-term tolerability, the drug may not be 
available for use at the new dose until possibly even 2020. It is 
therefore likely to take 9 years from now for there to be enough 
evidence that 20 mg stavudine is safe and non-inferior to tenofovir, 
and could be used to replace tenofovir in first-line regimens.
If current price trends continue, it is likely the anticipated cost 
savings associated with stavudine could be overtaken by expected 
further price reductions for tenofovir and other components of the 
first-line regimen, by the time stavudine 20 mg would be ready 
for use. It is worth noting that a three-drug one-pill-once-a-
day regimen containing efavirenz and tenofovir is now priced at 
roughly half what stavudine-based Triomune cost when it was first 
introduced a decade ago.
Further, even greater potential savings could be achieved if the 
tenofovir prodrug GS 7340, now in phase II by Gilead Sciences, is 
approved at a low milligram dose. Results will be available within a 
similar time frame to those from the 96-week stavudine 20 mg trial. 
A recent announcement by Gilead of an agreement with Tibotec to 
develop a fixed-dose combination of darunavir, emtricitabine, GS 
7340 and cobicistat with ‘less than one tenth of the amount of the 
300 mg of tenofovir disoproxil fumarate contained in Viread and 
Truvada’ suggests that this is feasible.11 Chimerix Inc. also has a 
promising tenofovir pro-drug in development, CMX-157.
Other drugs in late-stage development such as the integrase 
inhibitor dolutegravir (50 mg once daily) also offer potential 
savings on manufacturing and could end up being cheaper than 
stavudine 20 mg by the time it would become available. 
9. Stavudine has low acceptability in the community. Finally, 
and most importantly, the continued use of stavudine and the 
proposed trial has raised opposition from people directly affected 
by its continued use. As an example, the Malawi Network of People 
Living with HIV/AIDS (MANET+) recently held a press briefing, 
as the slow pace for phasing out current use of this drug in their 
country concerns them. Despite the funding crisis, the Malawi 
government has a priority for this to be completed by June 2012.12
It is unclear why the Bill and Melinda Gates Foundation – who are 
in discussion with the investigators about funding the proposal – 
consider this study to be a priority. It seems an aberration in an 
otherwise carefully considered strategy for supporting research 
into the optimisation of ART for resource-limited settings. 
This includes the ENCORE 1 study of low-dose efavirenz, the 
reformulation of tenofovir to increase its bioavailability (working 
with CHAI), and the development of innovative potentially long-
acting formulations.
For the reasons outlined above, research and the resources it 
requires, as well as activist pressure, should focus on increasing 
access to safer cost-saving alternatives to stavudine, not on seeking 
a comeback for a drug virtually abandoned in wealthy countries.
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